$2.91
8.79%
Nasdaq, Nov 16, 04:27 pm EST. Closed.
Why the stock moved Why the stock moved
ISIN
US75629V1044
Symbol
RXRX

Recursion Pharmaceuticals Stock price

$2.91
-0.56 16.16% 1M
+0.02 0.52% 6M
-1.19 28.97% YTD
-1.22 29.49% 1Y
-3.77 56.45% 3Y
-17.10 85.48% 5Y
-28.40 90.72% 10Y
-28.40 90.72% 20Y
Nasdaq, Closing price Mon, Nov 16 2026
-0.28 8.79%
ISIN
US75629V1044
Symbol
RXRX
Industry

AI Insights on Recursion Pharmaceuticals Insights AI Insights on Recursion Pharmaceuticals

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Recursion Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.8b
Enterprise Value
$1.3b
Net debt
positive
Cash
$549.9m
Shares outstanding
561.1m
Valuation
P/E
negative
P/S | estimate
26.5 | 35.6
EV/Sales | estimate
18.7 | 25.0
EV/FCF | ex SBC
negative | negative
P/B
2.0
Financial Health
Equity Ratio
76.7%
Return on Equity
-57.0%
ROCE
-45.1%
ROIC
-76.7%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$87.9m | 128.9%
SBC as % of FCF
-
SBC Growth 1Y
-25.6%
Share Count Growth 1Y
14.2%
Shareholder Yield
-14.2%
Financials
Revenue | estimate
$68.2m | $50.9m
EBITDA
$-460.4m
EBIT
$-495.0m
Net Income
$-475.7m
Free Cash Flow | ex SBC
$-312.5m | $-400.4m
Growth
Revenue | estimate
56.2% | -31.9%
EBITDA
28.8%
EBIT
31.6%
Net Income
33.5%
Free Cash Flow
30.2%
Margin
Gross
29.2%
EBITDA
-674.7%
EBIT
-725.4%
Net
-697.1%
Free Cash Flow | ex SBC
-458.0% | -586.9%
More
EPS
$-0.9
FCF per Share
$-0.6
Short interest
23.8%
Employees
600
Rev per Employee
$120.0k

Recursion Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Recursion Pharmaceuticals forecast:

8x Buy
62%
5x Hold
38%

Analyst Opinions

13 Analysts have issued a Recursion Pharmaceuticals forecast:

Buy
62%
Hold
38%

Recursion Pharmaceuticals Events

Past Events
NOV
3
Q3 2026 Earnings Call
14 days ago
SEP
15
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
AUG
11
Bank of America SMID Cap Virtual Conference
3 months ago
AUG
5
Q2 2026 Earnings Call
3 months ago
JUN
9
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
MAY
12
Bank of America Global Healthcare Conference 2026
6 months ago
MAY
6
Q1 2026 Earnings Call
7 months ago
APR
13
25th Annual Needham Virtual Healthcare Conference
7 months ago
MAR
17
2026 KeyBanc Capital Markets Healthcare Virtual Forum
8 months ago
MAR
9
Leerink Global Healthcare Conference 2026
8 months ago
MAR
2
TD Cowen 46th Annual Health Care Conference
9 months ago
FEB
25
Q4 2025 Earnings Call
9 months ago
JAN
16
28th Annual Needham Growth Conference
10 months ago
JAN
13
44th Annual J.P. Morgan Healthcare Conference
10 months ago
DEC
8
Special Call - Recursion Pharmaceuticals, Inc.
11 months ago
NOV
18
Jefferies London Healthcare Conference 2025
12 months ago
NOV
5
Q3 2025 Earnings Call
about one year ago

Financial data from Recursion Pharmaceuticals

Sep '26
+/-
%
68 68
56% 56%
100%
- Direct Costs 48 48
30% 30%
71%
20 20
177% 177%
29%
- Selling and Administrative Expenses 142 142
35% 35%
209%
- Research and Development Expense 338 338
28% 28%
495%
-460 -460
29% 29%
-675%
- Depreciation and Amortization 35 35
55% 55%
51%
EBIT (Operating Income) EBIT -495 -495
32% 32%
-725%
Net Profit -476 -476
34% 34%
-697%

In millions USD.

Don't miss a Thing! We will send you all news about Recursion Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Recursion Pharmaceuticals Stock News

Neutral
GlobeNewsWire
●
15 days ago
SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today reported financial results for the third quarter ended September 30, 2026, together with business updates highlighting continued clinical, pipeline and platform execution.
Neutral
GlobeNewsWire
●
15 days ago
Denver, Colorado, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced new positive Phase 2 data from the ongoing TUPELO trial of REC-4881, an investigational, oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The new analyses show that most patients had reductions in both...
More Recursion Pharmaceuticals News

Company Profile

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Dr. Khan
Employees 600
Founded 2013
Website www.recursion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today